Wang M, Munoz J, Goy A, Locke FL, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. J Clin Oncol 2022 Jun 4:JCO2102370. doi: 10.1200/JCO.21.02370.
PMID: 35658525